サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1424092

オピオイド誘発性便秘市場、シェア、規模、動向、産業分析レポート：有効成分別、処方タイプ別、投与経路別、流通チャネル別、地域別、セグメント予測、2024年～2032年

Opioid Induced Constipation Market Share, Size, Trends, Industry Analysis Report, By Active Ingredients; By Prescription Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032

出版日
ページ情報
英文 116 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.36円
オピオイド誘発性便秘市場、シェア、規模、動向、産業分析レポート：有効成分別、処方タイプ別、投与経路別、流通チャネル別、地域別、セグメント予測、2024年～2032年
出版日: 2024年01月24日
発行: Polaris Market Research
ページ情報: 英文 116 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界のオピオイド誘発性便秘市場規模は2032年までに39億3,000万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

オピオイドは、モルヒネ、トラマドール、フェンタニルを含むため、痛みから解放されるために最も使用されます。小売店やオンラインeコマースプラットフォームで鎮痛剤を入手しやすくなったことは、オピオイド誘発性便秘の著しい成長可能性を含め、マーケットプレースにおけるオピオイド需要に好影響を示しています。

製薬会社、政府、非政府機関による啓発キャンペーンの高まりは、オピオイド誘発性便秘症市場にプラスの影響を示しています。例えば、2023年、医薬品メーカーであるサリックス・ファーマシューティカルズは、他の2つの非営利団体とともに、12月5日をオピオイド誘発性便秘の啓発デーとし、この問題を取り巻く汚名に立ち向かうことを宣言しました。

多くの消費者の間でオピオイドの使用が増加していることから、オピオイド誘発性便秘症治療の需要が高まると予想されています。入手可能なデータによると、がんでなくともオピオイドを摂取している人のうち、約40～60％がオピオイド誘発性便秘（OIC）に罹患しています。

オピオイド関連薬の摂取に伴う便秘のリスクの高さと、潜在的な原因や適切な治療法を検討するための調査研究の増加は、市場の成長機会を拡大しています。例えば、National Library of Medicineに掲載された研究では、オピオイド誘発性便秘について調査し、この疾患を治療するための潜在的な治療法と非治療法について検討しました。

さらに、オピオイドの使用は、がん患者が痛みを和らげるために使用することが増加していることと関連している可能性があります。製薬の専門家によると、がん治療のためにオピオイドを服用した患者の約60～90％がオピオイド誘発性便秘に苦しんでいます。オピオイド誘発性便秘の患者は、主にがんの痛みに直面している人々にとって、日々の生活活動においてより多くの困難に直面する可能性が高いです。

さらに、研究活動は、オピオイド誘発性便秘に苦しむ患者に対する効果的な治療法の創出にプラスの影響を与えています。例えば、2024年の研究では、オピオイド誘発性便秘とラットの大腸腸管神経叢におけるP2Y1受容体との関係を明らかにすることに焦点が当てられています。

オピオイド誘発性便秘市場レポート・ハイライト

オピオイド誘発性便秘の治療薬としての可能性から、ナロキセゴール部門が最も速いペースで成長すると思われます。

医師による診察の重要性が高まっていることから、処方薬セグメントが最大のシェアを占める。

経口剤セグメントは、主に治療摂取の容易さと高い有効性により、市場を独占しています。

アジア太平洋地域は、高齢者人口の割合が多いことから、最も速いペースで推移するものと思われます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のオピオイド誘発性便秘市場に関する洞察

  • オピオイド誘発性便秘- 業界スナップショット
  • オピオイド誘発性便秘市場力学
    • 促進要因と機会
      • 高齢者の存在
      • オピオイド処方の大幅な増加
    • 抑制要因と課題
      • マーケットプレースにおけるオピオイドの使用の減少
  • PESTLE分析
  • オピオイド誘発性便秘業界の動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界のオピオイド誘発性便秘市場：有効成分別

  • 主な調査結果
  • イントロダクション
  • ナロキセゴル
  • ルビプロストン
  • 臭化メチルナルトレキソン
  • ドキュサートナトリウム
  • その他

第6章 世界のオピオイド誘発性便秘市場、処方タイプ別

  • 主な調査結果
  • イントロダクション
  • 市販薬
  • 処方箋、自然療法

第7章 世界のオピオイド誘発性便秘市場、投与経路別

  • 主な調査結果
  • イントロダクション
  • 経口
  • 非経口
  • その他

第8章 世界のオピオイド誘発性便秘市場、流通チャネル別

  • 主な調査結果
  • イントロダクション
  • 病院薬局
  • オンライン薬局
  • 小売薬局

第9章 世界のオピオイド誘発性便秘市場、地域別

  • 主な調査結果
  • イントロダクション
    • オピオイド誘発性便秘市場評価、地域、2019-2032年
  • オピオイド誘発性便秘市場-北米
    • 北米：オピオイド誘発性便秘市場、有効成分別、2019～2032年
    • 北米：オピオイド誘発性便秘市場、流通チャネル別、2019-2032年
    • 北米：オピオイド誘発性便秘市場、処方タイプ別、2019～2032年
    • 北米：オピオイド誘発性便秘市場、投与経路別、2019～2032年
    • オピオイド誘発性便秘市場-米国
    • オピオイド誘発性便秘市場- カナダ
  • オピオイド誘発性便秘市場- 欧州
    • 欧州：オピオイド誘発性便秘市場、有効成分別、2019～2032年
    • 欧州：オピオイド誘発性便秘市場、流通チャネル別、2019～2032年
    • 欧州：オピオイド誘発性便秘市場、処方タイプ別、2019～2032年
    • 欧州：オピオイド誘発性便秘市場、投与経路別、2019～2032年
    • オピオイド誘発性便秘市場- 英国
    • オピオイド誘発性便秘市場- フランス
    • オピオイド誘発性便秘市場- ドイツ
    • オピオイド誘発性便秘市場- イタリア
    • オピオイド誘発性便秘市場- スペイン
    • オピオイド誘発性便秘市場- オランダ
    • オピオイド誘発性便秘市場- ロシア
  • オピオイド誘発性便秘市場- アジア太平洋
    • アジア太平洋：オピオイド誘発性便秘市場、有効成分別、2019～2032年
    • アジア太平洋：オピオイド誘発性便秘市場、流通チャネル別、2019～2032年
    • アジア太平洋：オピオイド誘発性便秘市場、処方タイプ別、2019～2032年
    • アジア太平洋：オピオイド誘発性便秘市場、投与経路別、2019～2032年
    • オピオイド誘発性便秘市場- 中国
    • オピオイド誘発性便秘市場- インド
    • オピオイド誘発性便秘市場- 日本
    • オピオイド誘発性便秘市場- マレーシア
    • オピオイド誘発性便秘市場- インドネシア
    • オピオイド誘発性便秘市場- 韓国
  • オピオイド誘発性便秘市場-中東およびアフリカ
    • 中東およびアフリカ：オピオイド誘発性便秘市場、有効成分別、2019～2032年
    • 中東およびアフリカ：オピオイド誘発性便秘市場、流通チャネル別、2019～2032年
    • 中東およびアフリカ：オピオイド誘発性便秘市場、処方タイプ別、2019～2032年
    • 中東およびアフリカ：オピオイド誘発性便秘市場、投与経路別、2019～2032年
    • オピオイド誘発性便秘市場- サウジアラビア
    • オピオイド誘発性便秘市場- 南アフリカ
    • オピオイド誘発性便秘市場- イスラエル
    • オピオイド誘発性便秘市場- アラブ首長国連邦
  • オピオイド誘発性便秘市場-ラテンアメリカ
    • ラテンアメリカ：オピオイド誘発性便秘市場、有効成分別、2019～2032年
    • ラテンアメリカ：オピオイド誘発性便秘市場、流通チャネル別、2019-2032年
    • ラテンアメリカ：オピオイド誘発性便秘市場、処方タイプ別、2019～2032年
    • ラテンアメリカ：オピオイド誘発性便秘市場、投与経路別、2019～2032年
    • オピオイド誘発性便秘市場- メキシコ
    • オピオイド誘発性便秘市場- ブラジル
    • オピオイド誘発性便秘市場- アルゼンチン

第10章 競合情勢

  • 拡張と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第11章 企業プロファイル

  • Abbott（US）
  • Aurobindo Pharma（India）
  • Bayer AG（Germany）
  • Boehringer Ingelheim International GmbH.（Germany）
  • Bristol Myers Squibb Company（US）
  • Cosmo Pharmaceuticals（Ireland）
  • Daewoong Pharmaceutical Company（South Korea）
  • F. Hoffmann-La Roche Ltd（Switzerland）
  • Fresenius Kabi AG（Germany）
  • GSK Plc.（UK）
  • Hikma Pharmaceuticals PLC（UK）
  • Merck & Co Inc.（US）
  • Mylan NV（US）
  • Novartis AG（Switzerland）
  • Pfizer Inc（US）
図表

List of Tables

  • Table 1 Global Opioid Induced Constipation Market, by Active Ingredients, by Region, 2019-2032 (USD Billion)
  • Table 2 Global Opioid Induced Constipation Market, by Prescription Type, by Region, 2019-2032 (USD Billion)
  • Table 3 Global Opioid Induced Constipation Market, by Route of Administration, by Region, 2019-2032 (USD Billion)
  • Table 4 Global Opioid Induced Constipation Market, by Distribution Channel, by Region, 2019-2032 (USD Billion)
  • Table 5 Opioid Induced Constipation Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 6 North America: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 7 North America: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 8 North America: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 9 North America: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 10 U.S.: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 11 U.S.: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 12 U.S.: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 13 U.S.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 14 Canada: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 15 Canada: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 16 Canada: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 17 Canada: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 18 Europe: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 19 Europe: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 20 Europe: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 21 Europe: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 22 Germany: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 23 Germany: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 25 Germany: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 26 France: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 27 France: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 28 France: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 29 France: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 30 UK: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 31 UK: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 32 UK: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 33 UK: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 34 Italy: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 35 Italy: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 36 Italy: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 37 Italy: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 38 Netherlands: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 39 Netherlands: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 40 Netherlands: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 41 Netherlands: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 42 Spain: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 43 Spain: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 44 Spain: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 45 Spain: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 46 Russia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 47 Russia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 48 Russia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 49 Russia: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 50 Asia Pacific: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 51 Asia Pacific: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 52 Asia Pacific: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 53 Asia Pacific: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 54 China: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 55 China: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 56 China: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 57 China: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 58 Japan: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 59 Japan: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 60 Japan: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 61 Japan: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 62 India: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 63 India: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 64 India: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 65 India: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 66 Indonesia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 67 Indonesia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 68 Indonesia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 69 Indonesia: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 70 Malaysia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 71 Malaysia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 72 Malaysia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 73 Malaysia: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 74 South Korea: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 75 South Korea: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 76 South Korea: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 77 South Korea: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 78 Latin America: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 79 Latin America: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 80 Latin America: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 81 Latin America: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 82 Brazil: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 83 Brazil: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 84 Brazil: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 85 Brazil: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 86 Mexico: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 87 Mexico: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 88 Mexico: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 89 Mexico: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 90 Argentina: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 91 Argentina: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 92 Argentina: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 93 Argentina: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 94 Middle East & Africa: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 95 Middle East & Africa: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 96 Middle East & Africa: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 97 Middle East & Africa: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 98 UAE: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 99 UAE: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 100 UAE: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 101 UAE: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 102 Saudi Arabia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 103 Saudi Arabia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 104 Saudi Arabia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 105 Saudi Arabia: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 106 South Africa: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 107 South Africa: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 108 South Africa: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 109 South Africa: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 110 Israel: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 111 Israel: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 112 Israel: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 113 Israel: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Opioid Induced Constipation Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Distribution Channel
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Active Ingredients
  • Figure 7. Global Opioid Induced Constipation Market, by Active Ingredients, 2021 & 2030 (USD Billion)
  • Figure 8. Market by Distribution Channel
  • Figure 9. Global Opioid Induced Constipation Market, by Distribution Channel, 2021 & 2030 (USD Billion)
  • Figure 10. Market by Prescription Type
  • Figure 11. Global Opioid Induced Constipation Market, by Prescription Type, 2021 & 2030 (USD Billion)
  • Figure 12. Market by Route of Administration
  • Figure 13. Global Opioid Induced Constipation Market, by Route of Administration, 2021 & 2030 (USD Billion)
目次
Product Code: PM4344

The global opioid induced constipation market size is expected to reach USD 3.93 billion by 2032, according to a new study by Polaris Market Research. The report "Opioid Induced Constipation Market Share, Size, Trends, Industry Analysis Report, By Active Ingredients; By Prescription Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Opioids are most used to get relief from pain, as they include morphine, tramadol, and fentanyl. The increased accessibility of painkillers at retail and online e-commerce platforms is showing a positive impact on the demand for opioids in the marketplace, including significant growth potential for opioid-induced constipation.

The rising awareness campaigns by pharmaceutical companies, governments, and non-government agencies are demonstrating a positive impact on the opioid-induced constipation market. For instance, in 2023, Salix Pharmaceuticals, a drug manufacturer, along with the other two non-profit organisations, declared December 5 as the opioid-induced constipation awareness day to confront the stigmas surrounding the issue.

The rising use of opioids among the larger consumer base is expected to boost demand for opioid-induced constipation treatment. According to the available data, among the individuals who consumed opioids without cancer, around 40-60% of the people get opioid-induced constipation (OIC).

The higher risk of constipation with the intake of opioid-related drugs, along with the growing research studies to review the potential causes and suitable treatments, are showing wider growth opportunities for the market. For instance, a study published in the National Library of Medicine explored opioid-induced constipation and reviewed potential therapeutic and non-therapeutic treatments to treat the disease.

Furthermore, the use of opioids can be related to the rising use by cancer patients to get pain relief. According to pharmaceutical experts, approximately 60 to 90% of patients who took the opioid for cancer treatment suffered from opioid-induced constipation. Opioid-induced constipation patients are likely to face more difficulties in day-to-day life activities, primarily those facing cancer pain.

Moreover, research activities are positively influencing the creation of effective treatments for patients suffering from opioid-induced constipation. For instance, a 2024 study focused on finding the relationship between opioid-induced constipation and the P2Y1 receptor in the colonic myenteric plexus of rats.

Opioid Induced Constipation Market Report Highlights

Naloxegol segment will grow at the fastest pace, due to its potential for treating opioid induced constipation issues.

Prescription segment held the largest share, owing to the rising importance of doctor consultation.

Oral segment dominated the market, primarily due to its ease of treatment intake and higher effectiveness.

Asia Pacific will register the fastest pace, attributable to the presence of the large proportion of elderly population.

The global players include Abbott, Aurobindo Pharma, Bayer, Boehringer Ingelheim International, & Bristol Myers Squibb Company.

Polaris Market Research has segmented the opioid induced constipation market report based on active ingredients, prescription type, route of administration, distribution channel and region:

Opioid Induced Constipation, Active Ingredients Outlook (Revenue - USD Billion, 2019 - 2032)

  • Naloxegol
  • Lubiprostone
  • Methylnaltrexone Bromide
  • Docusate Sodium
  • Others

Opioid Induced Constipation, Prescription Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Over The Counter Medicines
  • Prescription, Natural Remedies

Opioid Induced Constipation, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

  • Oral
  • Injectable
  • Others

Opioid Induced Constipation, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Opioid Induced Constipation, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Opioid Induced Constipation Market Insights

  • 4.1. Opioid Induced Constipation - Industry Snapshot
  • 4.2. Opioid Induced Constipation Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. The presence of an elderly population
      • 4.2.1.2. The significant rise in opioid prescriptions
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. The declining use of opioids in the marketplace
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Opioid Induced Constipation Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Opioid Induced Constipation Market, by Active Ingredients

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • 5.3. Naloxegol
    • 5.3.1. Global Opioid Induced Constipation Market, by Naloxegol, by Region, 2019-2032 (USD Billion)
  • 5.4. Lubiprostone
    • 5.4.1. Global Opioid Induced Constipation Market, by Lubiprostone, by Region, 2019-2032 (USD Billion)
  • 5.5. Methylnaltrexone Bromide
    • 5.5.1. Global Opioid Induced Constipation Market, by Methylnaltrexone Bromide, by Region, 2019-2032 (USD Billion)
  • 5.6. Docusate Sodium
    • 5.6.1. Global Opioid Induced Constipation Market, by Docusate Sodium, by Region, 2019-2032 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Opioid Induced Constipation Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Opioid Induced Constipation Market, by Prescription Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • 6.3. Over The Counter Medicines
    • 6.3.1. Global Opioid Induced Constipation Market, by Over The Counter Medicines, by Region, 2019-2032 (USD Billion)
  • 6.4. Prescription, Natural Remedies
    • 6.4.1. Global Opioid Induced Constipation Market, by Prescription, Natural Remedies, by Region, 2019-2032 (USD Billion)

7. Global Opioid Induced Constipation Market, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • 7.3. Oral
    • 7.3.1. Global Opioid Induced Constipation Market, by Oral, by Region, 2019-2032 (USD Billion)
  • 7.4. Parenteral
    • 7.4.1. Global Opioid Induced Constipation Market, by Parenteral, by Region, 2019-2032 (USD Billion)
  • 7.5. Others
    • 7.5.1. Global Opioid Induced Constipation Market, by Others, by Region, 2019-2032 (USD Billion)

8. Global Opioid Induced Constipation Market, by Distribution Channel

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.3. Hospital Pharmacy
    • 8.3.1. Global Opioid Induced Constipation Market, by Hospital Pharmacy, by Region, 2019-2032 (USD Billion)
  • 8.4. Online Pharmacy
    • 8.4.1. Global Opioid Induced Constipation Market, by Online Pharmacy, by Region, 2019-2032 (USD Billion)
  • 8.5. Retail Pharmacy
    • 8.5.1. Global Opioid Induced Constipation Market, by Retail Pharmacy, by Region, 2019-2032 (USD Billion)

9. Global Opioid Induced Constipation Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Opioid Induced Constipation Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 9.3. Opioid Induced Constipation Market - North America
    • 9.3.1. North America: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
    • 9.3.2. North America: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.3.3. North America: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
    • 9.3.4. North America: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.3.5. Opioid Induced Constipation Market - U.S.
      • 9.3.5.1. U.S.: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.3.5.2. U.S.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.3.5.3. U.S.: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.3.5.4. U.S.: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.3.6. Opioid Induced Constipation Market - Canada
      • 9.3.6.1. Canada: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.3.6.2. Canada: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.3.6.3. Canada: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.3.6.4. Canada: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.4. Opioid Induced Constipation Market - Europe
    • 9.4.1. Europe: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
    • 9.4.2. Europe: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.3. Europe: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
    • 9.4.4. Europe: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.5. Opioid Induced Constipation Market - UK
      • 9.4.5.1. UK: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.5.2. UK: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.5.3. UK: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.5.4. UK: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.6. Opioid Induced Constipation Market - France
      • 9.4.6.1. France: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.6.2. France: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.6.3. France: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.6.4. France: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.7. Opioid Induced Constipation Market - Germany
      • 9.4.7.1. Germany: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.7.2. Germany: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.7.3. Germany: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.7.4. Germany: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.8. Opioid Induced Constipation Market - Italy
      • 9.4.8.1. Italy: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.8.2. Italy: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.8.3. Italy: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.8.4. Italy: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.9. Opioid Induced Constipation Market - Spain
      • 9.4.9.1. Spain: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.9.2. Spain: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.9.3. Spain: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.9.4. Spain: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.10. Opioid Induced Constipation Market - Netherlands
      • 9.4.10.1. Netherlands: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.10.2. Netherlands: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.10.3. Netherlands: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.10.4. Netherlands: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.11. Opioid Induced Constipation Market - Russia
      • 9.4.11.1. Russia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.11.2. Russia.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.11.3. Russia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.11.4. Russia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.5. Opioid Induced Constipation Market - Asia Pacific
    • 9.5.1. Asia Pacific: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
    • 9.5.2. Asia Pacific: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.3. Asia Pacific: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
    • 9.5.4. Asia Pacific: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.5. Opioid Induced Constipation Market - China
      • 9.5.5.1. China: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.5.5.2. China.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.5.3. China: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.5.5.4. China: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.6. Opioid Induced Constipation Market - India
      • 9.5.6.1. India: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.5.6.2. India.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.6.3. India: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.5.6.4. India: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.7. Opioid Induced Constipation Market - Japan
      • 9.5.7.1. Japan: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.5.7.2. Japan.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.7.3. Japan: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.5.7.4. Japan: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.8. Opioid Induced Constipation Market - Malaysia
      • 9.5.8.1. Malaysia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.5.8.2. Malaysia.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.8.3. Malaysia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.5.8.4. Malaysia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.9. Opioid Induced Constipation Market - Indonesia
      • 9.5.9.1. Indonesia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.5.9.2. Indonesia.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.9.3. Indonesia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.5.9.4. Indonesia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.10. Opioid Induced Constipation Market - South Korea
      • 9.5.10.1. South Korea: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.5.10.2. South Korea.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.10.3. South Korea: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.5.10.4. South Korea: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.6. Opioid Induced Constipation Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
    • 9.6.2. Middle East & Africa: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.3. Middle East & Africa: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
    • 9.6.4. Middle East & Africa: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.6.5. Opioid Induced Constipation Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.6.6. Opioid Induced Constipation Market - South Africa
      • 9.6.6.1. South Africa: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.6.6.2. South Africa: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.6.3. South Africa: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.6.6.4. South Africa: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.6.7. Opioid Induced Constipation Market - Israel
      • 9.6.7.1. Israel: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.6.7.2. Israel: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.7.3. Israel: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.6.7.4. Israel: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.6.8. Opioid Induced Constipation Market - UAE
      • 9.6.8.1. UAE: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.6.8.2. UAE: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.8.3. UAE: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.6.8.4. UAE: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.7. Opioid Induced Constipation Market - Latin America
    • 9.7.1. Latin America: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
    • 9.7.2. Latin America: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.7.3. Latin America: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
    • 9.7.4. Latin America: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.7.5. Opioid Induced Constipation Market - Mexico
      • 9.7.5.1. Mexico: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.7.5.2. Mexico: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.5.3. Mexico: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.7.5.4. Mexico: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.7.6. Opioid Induced Constipation Market - Brazil
      • 9.7.6.1. Brazil: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.7.6.2. Brazil: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.6.3. Brazil: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.7.6.4. Brazil: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.7.7. Opioid Induced Constipation Market - Argentina
      • 9.7.7.1. Argentina: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.7.7.2. Argentina: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.7.3. Argentina: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.7.7.4. Argentina: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Abbott (US)
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Aurobindo Pharma (India)
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Bayer AG (Germany)
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Boehringer Ingelheim International GmbH. (Germany)
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Bristol Myers Squibb Company (US)
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Cosmo Pharmaceuticals (Ireland)
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Daewoong Pharmaceutical Company (South Korea)
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. F. Hoffmann-La Roche Ltd (Switzerland)
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Fresenius Kabi AG (Germany)
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. GSK Plc. (UK)
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Hikma Pharmaceuticals PLC (UK)
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Merck & Co Inc. (US)
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13. Mylan NV (US)
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Novartis AG (Switzerland)
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
  • 11.15. Pfizer Inc (US)
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Benchmarking
    • 11.15.4. Recent Development